Aug 19, 2025 · Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...

Aug 20, 2025 · Viking Therapeutics (NASDAQ: VKTX) fell 42% on August 19, 2025, after Phase 2 results for its oral obesity pill VK2735 disappointed investors. The oral formulation led to up to 12.2% weight...

Aug 19, 2025 · Read Press Release for Viking Therapeutics (VKTX) published on Aug. 19, 2025 - Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity

SAN DIEGO, Aug. 19, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...

Get the latest Viking Therapeutics, Inc. (VKTX) stock news and headlines to help you in your trading and investing decisions.

Sep 3, 2025 · Stay up to date with all latest press releases from Viking Therapeutics, Inc. (VKTX).

Aug 16, 2025 · vktx news releases related vktx news releases and vktx press releases from the OTCMKTS NASDAQ and NYSE markets.

On August 19, 2025, Viking Therapeutics, Inc. issued a press release announcing top-line results from the Company’s Phase 2 clinical trial of the oral tablet formulation of VK2735.

Aug 26, 2025 · Read today's VKTX news from trusted media outlets at MarketBeat.

Novo Nordisk's Wegovy shows a stronger reduction in heart risks compared to Eli Lilly's tirzepatide in real-world data from the STEER study. Viking Therapeutics, Inc. (VKTX) reached …